Intellipharmaceutics Hit with Lawsuit for Allegedly Hyping Rexista

Intellipharmaceutics artificially inflated its stock prices during the NDA process for its oxycodone product Rexista, a new class-action lawsuit claims.
Source: Drug Industry Daily